An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children
- PMID: 24682000
An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children
Abstract
Context: Attention-deficit hyperactivity disorder (ADHD) is a clinically heterogeneous disorder of inattention, hyperactivity, and impulsivity or difficulty in controlling behavior. Psychostimulant medications remain the mainline treatment for children with ADHD; however, the average response rate to these medications is 70%, and up to 30% of children do not respond to these medications or are unable to tolerate such potential adverse effects as nausea, insomnia, and weight loss.
Objective: The study investigated the effectiveness of standardized Bacopa monnieri extract (SBME) in ameliorating the severity of the symptoms of ADHD in children.
Design: The clinical trial was conducted as an open-label study.
Setting: The study was conducted at the Center for Research in Mental Retardation (CREMERE) in Mumbai, India, from 2008 to 2010.
Participants: Thirty-one children were participants in the trial. They were 6-12 y of age, with an age of onset of ADHD before 7 y of age, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for ADHD.
Intervention: The children received SBME at a dose of 225 mg/d for a period of 6 mo. The specific SBME used in the study was BacoMind (M/s Natural Remedies, Bangalore, India).
Outcome measures: Subsequent to the screening of participants, the research team administered the Parent Rating Scale to assess the ADHD symptom scores at baseline, and the team administered it again at the end of the 6 mo of treatment.
Results: SBME significantly reduced the subtests scores of ADHD symptoms, except for social problems. The symptom scores for restlessness were reduced in 93% of children, whereas improvement in self-control was observed in 89% of the children. The attention-deficit symptoms were reduced in 85% of children. Similarly, symptom scores for learning problems, impulsivity, and psychiatric problems were reduced for 78%, 67%, and 52% of children, respectively. It was observed that 74% of the children exhibited up to a 20% reduction, while 26% of children showed between a 21% and a 50% reduction in the total subtests scores.
Conclusion: Standardized extract of B monnieri was found to be effective in alleviating the symptoms of ADHD and was well-tolerated by the children.
Similar articles
-
Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.Pediatrics. 2004 Nov;114(5):e541-7. doi: 10.1542/peds.2004-0844. Pediatrics. 2004. PMID: 15520087
-
A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI 08) on Hyperactivity and Inattention in Male Children and Adolescents: BACHI Study Protocol (ANZCTRN12612000827831).Nutrients. 2015 Dec 2;7(12):9931-45. doi: 10.3390/nu7125507. Nutrients. 2015. PMID: 26633481 Free PMC article. Clinical Trial.
-
Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.Curr Med Res Opin. 2006 Dec;22(12):2457-65. doi: 10.1185/030079906X148300. Curr Med Res Opin. 2006. PMID: 17257460 Clinical Trial.
-
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.Clin Ther. 2009 Jan;31(1):142-76. doi: 10.1016/j.clinthera.2009.01.015. Clin Ther. 2009. PMID: 19243715 Review.
-
A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations.Complement Ther Med. 2016 Dec;29:56-62. doi: 10.1016/j.ctim.2016.09.002. Epub 2016 Sep 4. Complement Ther Med. 2016. PMID: 27912958 Review.
Cited by
-
Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis.Antioxidants (Basel). 2024 Mar 25;13(4):393. doi: 10.3390/antiox13040393. Antioxidants (Basel). 2024. PMID: 38671841 Free PMC article. Review.
-
Attention-deficit/hyperactivity disorder and inflammation: natural product-derived treatments-a review of the last ten years.Inflammopharmacology. 2023 Dec;31(6):2939-2954. doi: 10.1007/s10787-023-01339-1. Epub 2023 Sep 23. Inflammopharmacology. 2023. PMID: 37740887 Review.
-
Herbal medicines in the treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD): An updated systematic review of clinical trials.Avicenna J Phytomed. 2023 Jul-Aug;13(4):338-353. doi: 10.22038/AJP.2022.21115. Avicenna J Phytomed. 2023. PMID: 37663386 Free PMC article. Review.
-
Phytotherapy for Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review and Meta-analysis.Front Pharmacol. 2022 May 3;13:827411. doi: 10.3389/fphar.2022.827411. eCollection 2022. Front Pharmacol. 2022. PMID: 35592415 Free PMC article.
-
A systematic review of tools used to screen and assess for externalising behaviour symptoms in low and middle income settings.Glob Ment Health (Camb). 2019 Jul 15;6:e13. doi: 10.1017/gmh.2019.11. eCollection 2019. Glob Ment Health (Camb). 2019. PMID: 31391945 Free PMC article. Review.